LKFT Overview

Lakefront Biotherapeutics NV is a Belgium‑based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal‑making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical‑stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in‑house cell therapy platforms. It builds a portfolio of clinical‑stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.

Wall Street analysts forecast LKFT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LKFT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lakefront Biotherapeutics NV revenue for the last quarter amounts to 6.48M USD, decreased -91.36

Lakefront Biotherapeutics NV. EPS for the last quarter amounts to 0.22 USD, decreased -109.44

Lakefront Biotherapeutics NV (LKFT) has 452 emplpoyees as of June 05 2026.

Today LKFT has the market capitalization of 1.85B USD.